skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Three-Year Outcomes of Breast Intensity-Modulated Radiation Therapy With Simultaneous Integrated Boost

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1]; ; ;  [1]
  1. Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA (United States)

Purpose: To report our clinical experience using breast intensity-modulated radiation therapy with simultaneous integrated boost (SIB-IMRT). Methods and Materials: Retrospective review identified 354 Stage 0 to III breast cancer patients treated with SIB-IMRT after conservative surgery between 2003 and 2006. The most common fractionation (89%) simultaneously delivered 1.8 Gy to the ipsilateral breast tissue and 2.14 Gy to the resection cavity, yielding a breast dose of 45 Gy (25 fractions) and cavity dose 59.92 Gy (28 fractions), biologically equivalent for tumor control to 45 Gy to the breast with sequential 16-Gy boost (33 fractions). Results: A total of 356 breasts in 354 patients were treated: 282 with invasive breast cancer, and 74 with ductal carcinoma in situ (DCIS). For left breast radiation, median cardiac V{sub 15} was 2.9% and left ventricular V{sub 15} 1.7%. Median follow-up was 33 months (range, 4-73 months). Acute toxicity was Grade 1 in 57% of cases, Grade 2 in 43%, and Grade 3 in <1%. For invasive breast cancer, the 3-year overall survival was 97.6% and risk of any locoregional recurrence was 2.8%. For ductal carcinoma in situ, 3-year overall survival was 98% and risk of locoregional recurrence 1.4%. In 142 cases at a minimum of 3 years follow-up, global breast cosmesis was judged by physicians as good or excellent in 96.5% and fair in 3.5%. Conclusions: Breast SIB-IMRT reduced treatment duration by five fractions with a favorable acute toxicity profile and low cardiac dose for left breast treatment. At 3 years, locoregional control was excellent, and initial assessment suggested good or excellent cosmesis in a high percentage of evaluable patients.

OSTI ID:
21372303
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 77, Issue 2; Other Information: DOI: 10.1016/j.ijrobp.2009.05.042; PII: S0360-3016(09)00824-4; Copyright (c) 2010 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Intraoperative Radiotherapy in Early-Stage Breast Cancer: Results of the Montpellier Phase II Trial
Journal Article · Mon Mar 01 00:00:00 EST 2010 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21372303

Five-year Local Control in a Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy With an Incorporated Boost for Early Stage Breast Cancer
Journal Article · Thu Nov 15 00:00:00 EST 2012 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21372303

Partial Breast Radiation Therapy With Proton Beam: 5-Year Results With Cosmetic Outcomes
Journal Article · Sat Nov 01 00:00:00 EDT 2014 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21372303